EUVIMEDEUVIMED entdecken
Open Access

A Bayesian latent-subgroup platform design for dose optimization

Rongji Mu iD, Xiaojiang Zhan, Rui Sammi Tang, Ying Yuan iD

Biometrics · 2024

DOI: 10.1093/biomtc/ujae093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, 2024. Verfasst von Rongji Mu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Hauptthemen laut MEDLINE: Bayes Theorem, Maximum Tolerated Dose, Computer Simulation, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Natural Science Foundation of China, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US Food and Drug Administration launched Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development, calling for the paradigm shift from finding the maximum tolerated dose to the identification of optimal biological dose (OBD). Motivated by a real-world drug development program, we propose a master-protocol-based platform trial design to simultaneously identify OBDs of a new drug, combined with standards of care or other novel agents, in multiple indications. We propose a Bayesian latent subgroup model to accommodate the treatment heterogeneity across indications, and employ Bayesian hierarchical models to borrow information within subgroups. At each interim analysis, we update the subgroup membership and dose–toxicity and –efficacy estimates, as well as the estimate of the utility for risk-benefit tradeoff, based on the observed data across treatment arms to inform the arm-specific decision of dose escalation and de-escalation and identify the OBD for each arm of a combination partner and an indication. The simulation study shows that the proposed design has desirable operating characteristics, providing a highly flexible and efficient way for dose optimization. The design has great potential to shorten the drug development timeline, save costs by reducing overlapping infrastructure, and speed up regulatory approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bayes TheoremMaximum Tolerated DoseComputer SimulationDose-Response Relationship, DrugAntineoplastic AgentsHumansDrug DevelopmentModels, StatisticalUnited StatesUnited States Food and Drug AdministrationNeoplasmsResearch DesignBiometryAdaptive Clinical Trials as Topic

Stichwörter der Autor:innen

Bayesian adaptive designlatent subgroupoptimal biological doseplatform trial

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Global Biometrics, Servier, Boston, MA 02210, United States.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

ORCID-Profile: Rongji Mu, Ying Yuan

Förderung

  • NCI NIH HHS
  • National Natural Science Foundation of China
  • National Cancer Institute

Zitieren

APA

Mu, R., Zhan, X., Tang, R. S., & Yuan, Y. (2024). A Bayesian latent-subgroup platform design for dose optimization. Biometrics. https://doi.org/10.1093/biomtc/ujae093

Vancouver

Mu R, Zhan X, Tang RS, Yuan Y. A Bayesian latent-subgroup platform design for dose optimization. Biometrics. 2024. doi:10.1093/biomtc/ujae093

BibTeX
@article{Mu2024,
  author = {Mu, Rongji and Zhan, Xiaojiang and Tang, Rui Sammi and Yuan, Ying},
  title = {A Bayesian latent-subgroup platform design for dose optimization},
  journal = {Biometrics},
  year = {2024},
  doi = {10.1093/biomtc/ujae093}
}
Kostenlos starten →